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Abstract:
Prostaglandin E 2 (PGE 2 ) controls numerous physiological functions through a family of cognate G protein coupled receptors (EP1-EP4). Targeting specific EP receptors might be therapeutically useful and reduce side effects associated with non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors that block prostanoid synthesis. Recently, systemic immune challenge and inflammatory cytokines were shown to increase expression of the synthetic enzymes for PGE 2 in the adrenal gland. Catecholamines and other hormones, released from adrenal chromaffin cells in response to Ca 2+ influx through voltage-gated Ca 2+ channels, play central roles in homeostatic function and the coordinated stress response. However, chronic elevation of circulating catecholamines contributes to the pathogenesis of hypertension and heart failure. Here we investigated the EP receptor(s) and cellular mechanisms by which PGE 2 might modulate chromaffin cell function. PGE 2 did not alter resting intracellular [Ca 2+ ] or the peak amplitude of nicotinic acetylcholine receptor currents, but did inhibit Ca V 2 voltage-gated Ca 2+ channel currents (I Ca ). This inhibition was voltage-dependent and mediated by pertussis toxinsensitive G proteins, consistent with a direct Gβγ subunit-mediated mechanism common to other G i/o -coupled receptors. mRNA for all four EP receptors was detected, but using selective pharmacological tools and EP receptor knockout mice we demonstrated that EP3 receptors mediate the inhibition of I Ca . Finally, changes in membrane capacitance showed that Ca 2+ -dependent exocytosis was reduced in parallel with I Ca . To our knowledge this is the first study of EP receptor signaling in mouse chromaffin cells and identifies a molecular mechanism for paracrine regulation of neuroendocrine function by PGE 2 .
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Introduction
Catecholamines and other hormones released from adrenal chromaffin cells help maintain normal homeostatic function and play central roles in the coordinated response to acute stressors, for example during "fight-or-flight" sympathetic activation. Elevation of circulating catecholamines is closely correlated with hypertension and is a hallmark of chronic heart failure.
Indeed, specifically targeting the adrenal gland to inhibit catecholamine outflow in vivo improved cardiac function in rat models of heart failure, suggesting adrenal hormone release as a potential therapeutic target (Lymperopoulos et al., 2008) . In situ, acetylcholine (ACh) released from splanchnic nerve fibers activates nicotinic ACh receptors on the chromaffin cell causing membrane depolarization, opening of voltage-gated calcium channels, and influx of calcium that subsequently triggers exocytosis (Boarder et al., 1987) . Thus, as with neurons and other excitable cells, voltage-gated calcium channels play pivotal roles in chromaffin cell function.
The cells also express a variety of G protein coupled receptors (GPCRs) that orchestrate complex regulation of stimulus-secretion coupling. For example, chromaffin cells express autoreceptors for ATP (P2Y receptors), catecholamines (α-adrenergic) and enkephalin (μ-opioid receptors) that couple to G i/o -type G proteins and mediate autocrine/paracrine inhibition of catecholamine release through inhibition of voltage-gated calcium channels (Albillos et al., 1996; Currie and Fox, 1996; Harkins and Fox, 2000; Powell et al., 2000; Ulate et al., 2000) and other downstream targets (Chen et al., 2005; Yoon et al., 2008) .
In this study we investigated the effects of prostaglandin E 2 (PGE 2 ) on chromaffin cells. PGE 2 is produced in a variety of cell types through metabolism of arachidonic acid by cyclooxygenase (COX-1 or COX-2) and prostaglandin E synthases. It acts in an autocrine / paracrine manner, This article has not been copyedited and formatted. The final version may differ from this version.
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Mol # 68569 5 primarily through binding to a family of cognate GPCRs (EP1-EP4 receptors) (Breyer et al., 2001) , to control a variety physiological functions including: protection of the gastric mucosa, renal function, inflammation, pain, blood pressure, and secretion of hormones and neurotransmitters. Non-steroidal anti-inflammatory drugs such as aspirin and selective COX-2 inhibitors reduce production of PGE 2 , but also disrupt synthesis of other prostanoids and can cause serious side effects. One strategy to reduce these unwanted side-effects is to identify specific cellular functions of EP receptors and develop EP receptor subtype-selective drugs. For example, characterization of EP receptor signaling in smooth muscle suggests EP1 receptors could be targeted for antihypertensive treatment, and an EP3 receptor antagonist (DG-041) is under investigation for treatment of atherothrombosis (Guan et al., 2007; Heptinstall et al., 2008 ).
EP1 and EP3 receptors are expressed in the adrenal medulla (Breyer et al., 1993; Engstrom et al., 2008; Namba et al., 1993; Shibuya et al., 1999) along with the synthetic enzymes for PGE 2 (Engstrom et al., 2008; Ichitani et al., 2001) . Moreover, systemic immune challenge or circulating cytokines rapidly recruit dendritic cells and macrophages to the adrenal gland, increase the expression of COX-2 and PGE synthase, and presumably local PGE 2 production (Engstrom et al., 2008) . Thus the components are in place for local modulation of chromaffin cells by PGE 2 , but previous studies present confusing and contradictory findings: PGE 2 has been reported to increase (Karaplis et al., 1989; Marley et al., 1988; Yamada et al., 1988; Yokohama et al., 1988) or decrease (Karaplis et al., 1989) adrenal catecholamine release, elevate intracellular calcium levels (Mochizuki-Oda et al., 1991; Shibuya et al., 1999) , or inhibit voltagegated calcium channels (Currie et al., 2000) . In sympathetic neurons, which are closely related This article has not been copyedited and formatted. The final version may differ from this version. (Du and Role, 2001; Tan et al., 1998) as well as voltage-gated calcium channels (Ikeda, 1992 receptor knockouts (Guan et al., 2007) ), all on C57BL/6 background were euthanized using carbon dioxide followed by cervical dislocation. Adrenal glands were quickly harvested and placed in ice cold Magnesium Free Locke's solution containing (in mM):153 NaCl, 6 KCl, 2 NaH 2 PO 4 .7H 2 0, 1 NaH 2 PO 4 .H 2 0, 10 Glucose, 10 HEPES. The glands were trimmed of fat and the cortex dissected from the medullae. The medullae were incubated for 15 minutes at 37° C in a papain digestion solution (2.5 mg/ml papain, Genlantis, San Diego, CA), followed by another 10 minute incubation at 37° C in collagenase P (3 U/ml, Roche Diagnostics, Indianapolis, IN.).
Tissues were washed 2X with Locke's and transferred to growth medium consisting of: DMEM / F12/GlutaMAX (catalogue # 10565) (Invitrogen, Carlsbad, CA) supplemented with Hyclone defined fetal bovine serum (10%) (Fisher Scientific, Pittsburgh, PA) and penicillin (100 unit/ml) / streptomycin (100 μ g/ml), (Sigma Aldrich, St. Louis, MO). Tissues were then triturated with a 2 ml fire polished glass pipette coated in growth medium and allowed to settle. The cell containing supernatant was removed and plated on glass coverslips thinly coated in growth factor reduced Matrigel (BD Biosciences, Bedford, MA). Cells were allowed to settle and adhere to the coverslips for 2 hours before 2ml of growth medium was added to the coverslips. Cells were maintained at 37° C in a humidified, 5% CO 2 atmosphere and used 1-3 days post-isolation. Each cell preparation was from a single mouse. All experimental studies were approved by the IACUC of Vanderbilt University Medical Center.
This article has not been copyedited and formatted. The final version may differ from this version. Fig 3A) was due to the "dead space" in the perfusion system.
The amplitude of the sustained inward current activated by carbachol was determined by calculating the mean current amplitude over a 5 s period starting 30 s after carbachol application.
The mean current amplitude over this 5 s period was determined for each cell and then data pooled. The current amplitude was also calculated (mean over a 5 s period) at the end of the drug application to determine the extent to which the response declined.
Changes in membrane capacitance (ΔCm) were monitored in the perforated whole-cell recording configuration using a HEKA EPC10 amplifier in combination with PatchMaster data acquisition software (HEKA Electronik). The software lock-in module was used to implement the "sine + d.c." approach for estimating Cm. A sine wave (1 kHz, 20 mV peak -peak) was imposed on the holding potential of -80 mV and the assumed reversal potential was set to 0 mV. Membrane conductance was simultaneously calculated by the software and any cells that showed simultaneous changes in Cm and Gs were discarded. Cells were stimulated by two step depolarizations (to +10 mV, 100 ms duration) separated by 100 ms. The stimulus was repeated every three minutes. Membrane capacitance was averaged over a 50 ms period before the stimulus (baseline) and again 50 ms after the end of the stimulus to calculate ΔCm. After two This article has not been copyedited and formatted. The final version may differ from this version. Mol # 68569 10 control responses cells were exposed to 100 nM PGE 2 during the third response. The second control response was typically of equal or greater magnitude than the first and if this was not the case the cell was discarded due to concern about "rundown". For data analysis, cells were divided into those that responded to PGE 2 with decrease in I Ca amplitude >10% (group-1), and those in which I Ca was not inhibited (group-2) (see results for more discussion).
Data are reported as mean ± standard error of the mean and statistical significance was determined using paired or independent Student's t test as appropriate.
[Ca
2+
] i Measurements: were alternately excited at wavelengths of 340 nm and 380 nm and emission at 510 nm detected using a pixelfly digital camera as detailed previously (Dzhura et al., 2006 (Molecular Probes, Eugene OR). One or two cells in the field of view were selected in each experiment and after a 2-minute baseline were exposed to 1μM PGE 2 for 3-minutes and subsequently to a 50 mM KCl containing solution (by replacing an equimolar amount of NaCl in our standard extracellular solution -see below). This was done as a positive control for the assay -to ensure the cells were loaded with Fura-2 and responded to calcium elevations. It also served as a means to identify any non-excitable (i.e. non-chromaffin) cells as these typically fail to respond to KCl. Cells that had an unstable baseline or failed to respond robustly to KCl (>300 nM elevation) were excluded from analysis. Data analysis was performed using OriginPro software (OriginLab Corporation, Northampton, MA). 
RT-PCR.
Drugs and Solutions
Cells were perfused at a rate of ~ 4 ml/min with external solution consisting of (in mM): 136
NaCl, 2 KCl, 1 MgCl.6H 2 0, 10 Glucose, 10 HEPES, 10 CaCl.2H 2 0, pH 7.3 osmolarity ~ 305. All drugs were diluted (≥1000X) and perfused in this extracellular solution unless otherwise noted. This article has not been copyedited and formatted. The final version may differ from this version. 
Results
PGE 2 inhibits I Ca in mouse adrenal chromaffin cells
Given the pivotal roles of voltage-gated calcium channels in stimulus-secretion coupling and many other cellular functions we initially tested whether PGE 2 inhibited the calcium channel currents (I Ca ) in mouse chromaffin cells. The cells were voltage-clamped at -80 mV and stimulated with a 20 ms step-depolarization to evoke I Ca every 10 s (Fig 1A) . Application of 100 nM PGE 2 produced a significant and reversible inhibition of peak I Ca amplitude ( Fig 1A) in approximately 76% of cells tested under similar experimental conditions (conventional wholecell recording, n = 37 of 49 cells; N = 9 mice). The inhibition of I Ca was concentration dependent (Fig 1B) and the data fit well with a Boltzmann function that yielded a maximal inhibition of 40% and an EC 50 of 5.5 nM consistent with the low nM affinities reported for PGE 2 binding to EP receptors (Breyer et al., 2001 ).
The inhibition of I Ca by PGE 2 is voltage-dependent and mediated by pertussis toxinsensitive G proteins.
G protein coupled receptors (GPCRs) inhibit I Ca by several different mechanisms, but perhaps the most widespread and best understood pathway is mediated by direct binding of G protein βγ subunits to P/Q-type (Ca V 2.1) and N-type (Ca V 2.2) channels (Currie, 2010a) . Although there are exceptions, in most cases this pathway involves GPCRs that couple to pertussis toxin-sensitive G i/o -type G proteins. We and others have previously shown that P2Y purinergic receptors and μ -opioid receptors utilize this pathway to produce autocrine/paracrine inhibition of I Ca in chromaffin cells (Albillos et al., 1996; Currie and Fox, 1996; Powell et al., 2000) . To determine This article has not been copyedited and formatted. The final version may differ from this version. if PGE 2 acts through a G i/o -coupled GPCR we incubated isolated mouse chromaffin cells with pertussis toxin (300 ng/mL) for ~24-hours prior to whole-cell recording. Control cells were from the same cell preparations and were recorded on the same days as the pertussis toxin treated cells. As shown in figure 2A , the inhibition of I Ca produced by PGE 2 was virtually abolished in pertussis toxin treated cells (2 ± 2.6%, n = 6 compared to 31 ± 7.1%, n = 7, in control cells; p < 0.002). As a positive control we also used the P2Y receptor agonist ATP (100 μ M), as this is known to inhibit I Ca via pertussis toxin-sensitive G proteins in chromaffin cells (Currie and Fox, 1996) . The inhibition produced by ATP was also significantly reduced (29 ± 8.5 %, n = 7 in control cells compared to 7 ± 5.4 %, n = 6, in pertussis toxin treated cells; p < 0.05). These data confirmed that PGE 2 acts though a G i/o -coupled GPCR to inhibit I Ca .
A defining biophysical signature of direct Gβγ-mediated inhibition of N-and P/Q-type channels is reversal by a strongly depolarizing voltage-step. This reversal is thought to reflect transient dissociation of Gβγ from the channel at the depolarized membrane potential (for review see (Currie, 2010a) . Therefore, we used a prepulse facilitation protocol to determine if PGE 2 utilized this mechanism to inhibit I Ca in mouse chromaffin cells. Figure 2B illustrates a representative voltage command (upper) and current trace (lower). The cell was stimulated by two identical test pulses (P1 and P2), the second of which was preceded by a 50 ms step to +120 mV. PGE 2 significantly reduced the amplitude of I Ca during both P1 and P2 (Fig 2C) , but the prepulse (immediately preceding P2) significantly reduced this inhibition from 43 ± 6 % during P1 to 13 ± 3% during P2 (n = 6; p < 0.001) (Fig 2D) . Thus the inhibition of I Ca produced by PGE 2 was largely voltage-dependent although there was also a voltage-independent component to the This article has not been copyedited and formatted. The final version may differ from this version. Voltage-dependent inhibition of I Ca by other GPCRs preferentially targets the Ca V 2 family of calcium channels, in particular P/Q-type (Ca V 2.1) and N-type (Ca V 2.2) channels (Currie, 2010a) .
Mouse chromaffin cells are known to express Ca V 2 channels (P/Q-type and N-type and R-type channels) and also members of the Ca V 1 family (L-type channels) (Garcia et al., 2006) .
Consistent with previous reports we found that nitrendipine, a dihydropyridine antagonist of Ltype channels, blocked 41 ± 5 % (n = 7) of the whole-cell current. We did not systematically dissect the channel types comprising the non-L-type current, but previous reports indicate the majority is carried by N-and P/Q-type channels, with 10-20% accounted for by R-type and perhaps T-type channels (Garcia et al., 2006) . After block of N-type (Ca V 2.2) and P/Q-type (Ca V 2.1) channels by pre-incubation with ω -conotoxin GVIA (1.5 μ M) and ω -agatoxin IVA (400 nM) respectively, the inhibition by PGE 2 was dramatically reduced (7 ± 1%; n = 6; p < 0.05) confirming that N-and P/Q-type channels are the main target for this pathway.
Acute application of PGE 2 did not alter peak nicotinic acetylcholine receptor currents
In situ, chromaffin cells are directly innervated by cholinergic splanchnic nerve fibers.
Activation of nicotinic acetylcholine receptors (nAChRs) on the chromaffin cells causes membrane depolarization, activation of voltage-gated calcium channels and influx of calcium that triggers exocytosis. It has been reported that PGE 2 modulates nicotinic acetylcholine receptors in sympathetic neurons (Du and Role, 2001; Tan et al., 1998) , although we are not aware of any similar studies in chromaffin cells. However, it has been shown that inhibition of This article has not been copyedited and formatted. The final version may differ from this version. To test this possibility cells were voltage-clamped at a holding potential of -80 mV in the perforated whole-cell recording configuration and the bath was continuously perfused with fresh extracellular recording solution. Nicotinic ACh receptor currents were evoked by application of 100 µM carbachol for 45 seconds (Fig 3A) . Under these conditions the inward current was primarily due to the relatively non-desensitizing nACh receptors found in chromaffin cells.
After washout of carbachol the cells were allowed to recover for six minutes before exposure to 100 nM PGE 2 and a second application of 100 μM carbachol (in the continued presence of PGE 2 ) (Fig 3A) . Acute application of PGE 2 had no effect on the mean peak inward current evoked by carbachol (351 ± 65 pA in the presence of PGE 2 compared to 352 ± 63 pA before application of PGE 2 ; n = 8) (Fig 3B) . The inward current response did decay slightly during continued application of carbachol (9 ± 2% in control conditions) and this was significantly increased in the presence of PGE 2 (21 ± 3%; p < 0.01). ] i (82 ± 15 nM before and 85 ± 16 nM during application of PGE 2 ; n = 9 cells from 7 independent experiments) ( Fig 3C) .
mRNA for all four EP receptor subtypes was detected in mouse adrenal tissue.
The data presented above demonstrated that PGE 2 acts through a G i/o -coupled GPCR to inhibit I Ca in mouse chromaffin cells. Of the four known receptors for PGE 2 , termed EP1-EP4, only EP3 typically couples to G i/o -type G proteins, although it has been reported recently that EP1 receptors might also couple to G i/o at least in some cell types (Ji et al., 2010) . Both EP3 and EP1
receptors have been reported previously in the adrenal medulla (Breyer et al., 1993; Engstrom et al., 2008; Namba et al., 1993) .
To determine which EP receptors were expressed in the mouse adrenal gland we used RT-PCR. The adrenal gland was isolated as described in the methods section and kidney tissue, which expresses all four EP receptor subtypes, was isolated in parallel as a positive control. The adrenal cortex was dissected from the gland leaving the adrenal medulla for RNA isolation, however small traces of cortex were likely present. Three known splice variants of the EP3 receptor are found in mice: EP3 α , EP3 β and EP3 γ (Breyer et al., 2001; Irie et al., 1993) . These splice variants differ in their C-terminal tail and can exhibit different downstream signaling pathways and agonist dependent desensitization in heterologous expression systems. We detected mRNA for all three EP3 receptor splice variants in the mouse adrenal tissue (Fig 4A) .
This article has not been copyedited and formatted. The final version may differ from this version. We also detected mRNA for the EP1, EP2 and EP4 receptors (Fig 4B) . GAPDH was used as an internal standard and amplified in all tissues (data not shown).
Pharmacological evidence that EP3 receptors mediate the inhibition of I Ca by PGE 2 .
We showed that the inhibition of I Ca was abolished in pertussis toxin treated cells (Fig 2A) , so is mediated by G i/o -coupled GPCRs. While we detected mRNA for all four EP receptor subtypes in the mouse adrenal gland (Fig 4) , generally only EP3 receptors couple to G i/o (Breyer et al., 2001 ).
Therefore, we used EP receptor subtype selective agonists and antagonists to investigate the involvement of EP3 receptors. First we used the selective EP1/EP3 receptor agonist sulprostone (Fig 5A, B) . In these experiments we used perforated whole-cell recordings to maintain endogenous calcium buffering of the chromaffin cells. The inhibition produced by 100 nM PGE 2 (43 ± 6%, n = 15) was similar to that in conventional whole-cell recording. Sulprostone (100 nM) significantly reduced the amplitude of I Ca in six-out-of-seven cells by 41 ± 9% (n = 6) and this was not significantly different from the inhibition produced by 100 nM PGE 2 under the same recording conditions (p = 0.89).
It has been reported that DG-041 is a selective, non-competitive antagonist of EP3 receptors (Heptinstall et al., 2008) . Cells were stimulated every 10 seconds with a 20-ms step depolarization to evoke I Ca . DG-041 (30 nM) was applied to the cells for ~2 minutes before application of PGE 2 (100 nM). DG-041 alone had little effect on I Ca but completely blocked the inhibition produced by PGE 2 (2.0 ± 2.2 %, n = 9; Fig 5C, D) . Subsequent applications of PGE 2 after several minutes of washout of DG-041 also produced no inhibitory effect, suggesting DG-041 is functionally irreversible over the time course of our experiments. As a control we used ATP (100 Mol # 68569 21 9 %; n = 6). Taken together, our data using pharmacological approaches and knockout mice demonstrate the inhibition of I Ca by PGE 2 is mediated solely by EP3 receptors.
Effects of PGE 2 on Ca
2+
-dependent exocytosis.
Ca 2+ influx through voltage-gated calcium channels is the primary trigger for fusion of large dense core vesicles with the plasma membrane (i.e. Ca 2+ -dependent exocytosis). Inhibition of I Ca is thought to an important mechanism that controls neurosecretion and a number of GPCRs inhibit I Ca and exocytosis in parallel in adrenal chromaffin cells (Currie, 2010b; Garcia et al., 2006) . Membrane capacitance precisely reflects the surface area of a cell and transiently increases when secretory vesicles fuse with the plasma membrane. The magnitude of this increase (ΔCm) reflects the number of vesicles that have undergone exocytosis. We used perforated whole-cell recordings to measure I Ca and ΔCm evoked by two 100 ms steps from80mV to +10mV (Fig 7A) in chromaffin cells isolated from wild type mice. As already noted, cells could be separated into two groups based on the response of I Ca to application of PGE 2 . In this particular series of experiments PGE 2 (100 nM) inhibited the peak amplitude of I Ca in sevenout-of-twelve cells (group-1) by 41 ± 10% (n = 7; p < 0.005) but had no effect in the remaining five cells (group-2) (3 ± 4% decrease; n = 5; p = 0.41) (Fig 7B) . Application of 100 nM PGE 2 significantly reduced ΔCm in group-1 (those cells in which I Ca was inhibited) from 153 ± 40 fF to 68 ± 16 fF (n = 7, p < 0.03). ΔCm was also significantly smaller during application of PGE 2 in group-2, even though I Ca was not reduced in these cells (Fig 7C) . This might reflect other pathways recruited by PGE 2 to control exocytosis independent of I Ca and/or time-dependent rundown of the exocytotic response, but these possibilities will require further investigation.
Notably, the inhibition of ΔCm was significantly greater in group-1 cells (in which I Ca was also reduced) compared to group-2 cells (49 ± 7 %, n = 7 compared to 24 ± 4%, n = 5; p < 0.02) (Fig This article has not been copyedited and formatted. The final version may differ from this version. (Harkins and Fox, 2000; Powell et al., 2000; Ulate et al., 2000) .
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
Previous work has suggested that PGE 2 might modulate adrenal chromaffin cells, although the effects and EP receptors involved remained unclear. The synthetic enzymes for PGE 2 are present in the adrenal medulla, and cholinergic stimulation leads to release of prostaglandins from the intact adrenal gland (Ramwell et al., 1966) . Furthermore, a recent in vivo analysis showed that systemic immune challenge or circulating cytokines rapidly recruited dendritic cells and macrophages to the adrenal gland and increased the expression of COX-2 and PGE synthase (Engstrom et al., 2008) . Thus, periods of inflammation or stress might boost production of PGE 2 within the adrenal gland. We previously reported that PGE 2 inhibited I Ca in bovine chromaffin cells, although the receptor(s) and detailed mechanisms were not determined (Currie et al., 2000) . In contrast, others reported that PGE 2 stimulated calcium influx (Mochizuki-Oda et al., 1991) or released calcium from a ryanodine sensitive intracellular store, an effect attributed to EP1 receptors (Shibuya et al., 1999) . It has also been reported that PGE 2 inhibited nicotinic ACh receptors in sympathetic neurons (Tan et al., 1998) . To our knowledge this has not been tested in chromaffin cells, but if it were to occur it could reduce cholinergic excitation / membrane depolarization and thereby opening of voltage-gated calcium channels.
In the current paper we report that PGE 2 inhibited I Ca in mouse chromaffin cells through pertussis toxin-sensitive G proteins. The inhibition was voltage-dependent (reversed by strong membrane depolarization) and preferentially targeted Ca V 2 calcium channels (N-and P/Q-type channels). Thus, PGE 2 mimicked agonists of other G i/o -coupled GPCRs including P2Y receptors that inhibit I Ca in chromaffin cells (Albillos et al., 1996; Currie and Fox, 1996; Powell et al., This article has not been copyedited and formatted. The final version may differ from this version. . The inhibition by PGE 2 bore all the hallmarks of that mediated by Gβγ subunit binding to the calcium channels (for reviews see (Currie, 2010a) ). To unequivocally identify the EP receptor subtype(s) involved we used cells isolated from knockout mice that lack either the EP3 or EP1 receptors. To complement this genetic approach we used selective pharmacological tools including a recently described EP3 receptor antagonist, DG-041 (Heptinstall et al., 2008) . As this compound was not readily available it was made in the Vanderbilt Institute for Chemical Biology Chemical Synthesis Core. Our data provide conclusive evidence that EP3 receptors mediated the inhibition of I Ca by PGE 2 in chromaffin cells.
It should be noted that PGE 2 inhibited I Ca in approximately three-quarters of cells tested, presumably reflecting expression of the EP3 receptor in this subpopulation of cells. In the rodent adrenal medulla 70-80% of chromaffin cells express phenylethanolamine N-methyltransferase (PNMT), the enzyme that converts norepinephrine to epinephrine, so are termed "adrenergic" (Verhofstad et al., 1985) . The remainder lack PNMT and are termed "noradrenergic". There is evidence for differential expression of GPCRs in adrenergic vs. noradrenergic cells (Renshaw et al., 2000) , so it is interesting to speculate that EP3 receptor expression might be limited to the adrenergic cells and preferentially modulate epinephrine release. Further work will be required to determine if this is the case. It is also noteworthy that the EP3 receptor undergoes alternative splicing, leading to sequence diversity in the cytoplasmic C-terminus (Breyer et al., 2001) ). In recombinant systems all the splice variants couple to G i/o -type G proteins, but can also couple differentially to other effectors including G s , and G 12 -RhoA. Because extracellular ligand binding is not altered, pharmacological distinction of the EP3 splice variants is not possible.
Four alternatively spliced variants of the EP3 receptor have been identified in a bovine
This article has not been copyedited and formatted. The final version may differ from this version. , and we detected mRNA for all three murine splice variants (EP3 α , EP3 β and EP3 γ ) in the adrenal gland using RT-PCR (Fig 4) . However, a more detailed molecular analysis will be required to determine which splice variants are expressed in chromaffin cells and if additional non-G i/o -coupled signaling pathways are recruited.
In contrast to some previous reports (Mochizuki-Oda et al., 1991; Shibuya et al., 1999) , we found no evidence that PGE 2 can directly elevate [Ca 2+ ] i (Fig 3C) . PGE 2 had no effect on the holding current needed to voltage-clamp cells at -80 mV (i.e. did not open / close any channels)
( Fig 3A) , and had no effect on resting [Ca 2+ ] i in Fura-2 loaded cells ( Fig 3C) . It is possible there are species differences in the expression of EP receptor subtypes as none of the previous studies used mice. We also found that PGE 2 had no effect on the peak amplitude of whole-cell nicotinic ACh receptor currents evoked by bath application of carbachol for 45 s (Fig 3A, B) . However, we did note that there was a modest increase in current decay during the sustained application of carbachol in the presence of PGE 2 (21 ± 3%; p < 0.01 compared to 9 ± 2%). Although "nondesensitizing" α3β4* containing channels predominate in chromaffin cells, several other nicotinic receptor subunits are expressed in a species dependent manner, including the rapidly desensitizing α7 subunit (Lopez et al., 1998; Sala et al., 2008) . In chick sympathetic neurons PGE 2 inhibited the whole-cell nicotinic current, but closer analysis revealed opposing effects on different channel subtypes. In particular, the dominant 36pS channel was inhibited, but a 23 pS channel likely mediated by α7 containing receptors was potentiated by PGE 2 (Du and Role, 2001 ). Further studies using fast, brief agonist applications will be needed to fully address the effects of PGE 2 on nicotinic receptors, but our data do suggest that the predominant nonThis article has not been copyedited and formatted. The final version may differ from this version. Previous studies investigating the effects of PGE 2 on catecholamine secretion have all used large populations of cultured chromaffin cells or intact adrenal gland preparations and present somewhat inconclusive findings. In some cases PGE 2 inhibited release (Karaplis et al., 1989) , while others report that PGE 2 potentiated release (Marley et al., 1988; Yamada et al., 1988; Yokohama et al., 1988) . As discussed above, high concentrations of PGE 2 used in some of these studies raise the possibility of non-EP receptor involvement. Our data demonstrate for the first time that EP3 receptors utilize the same mechanism as P2Y, (Harkins and Fox, 2000; Powell et al., 2000; Ulate et al., 2000) . Exocytosis can be monitored in individual cells by tracking changes in membrane capacitance (ΔCm) that precisely reflect the surface area of a cell. The magnitude of
ΔCm reflects the number of vesicles that have undergone exocytosis. As previously reported for other GPCRs application of PGE 2 led to a robust inhibition of ΔCm (49 ± 7%) that paralleled inhibition of I Ca (41 ± 10%) (Fig 7) . There was also a modest decrease in ΔCm (24 ± 4%) in cells that showed no inhibition of I Ca . This might reflect a time-dependent rundown of the exocytotic response or the possibility that other mechanisms are recruited to control secretion.
Gβγ-mediated inhibition of catecholamine release independent from I Ca modulation has been reported for other G i/o -coupled receptors (Chen et al., 2005; Yoon et al., 2008) . We also detected mRNA for EP1, 2 and 4 receptors in the mouse adrenal gland, in addition to all three splice This article has not been copyedited and formatted. The final version may differ from this version. Mol # 68569 27 variants of the EP3 receptor (Fig 4) . Further detailed investigations will be required to determine if these receptors are expressed in chromaffin cells and what functional impact they might have.
However, our data clearly show that the inhibition of ΔCm was significantly greater when I Ca was also reduced (49 ± 7 %, n = 7 compared to 24 ± 4%, n = 5; p < 0.02) (Fig 7C) supporting the idea that inhibition of Ca 2+ entry by PGE 2 leads to a parallel inhibition exocytosis as reported for other G i/o -coupled GPCRs (Harkins and Fox, 2000; Powell et al., 2000; Ulate et al., 2000) .
To summarize, there is growing interest in developing subtype selective EP receptor drugs as therapeutic agents for a variety of disorders, so identitying the physiological roles distinct receptors play will be important for interpreting and predicting the impact of these drugs.
We have used a powerful combination of pharmacology and cells isolated from receptor knockout mice to demonstrate that prostaglandin EP3 receptors inhibit I Ca in adrenal chromaffin cells and that this results in a parallel inhibition of Ca 2+ -dependent exocytosis. To our knowledge this is the first study of EP receptor signaling in mouse chromaffin cells and identifies a cellular / molecular mechanism for paracrine regulation of neuroendocrine function by PGE 2 .
